0913693 B.C. Ltd. (REPCF) 股价，以美元计价

RepliCel Life Sciences Inc. is developing autologous cell therapies to treat conditions including chronic tendon injuries, pattern baldness and UV-damaged and aging skin. All products are based on RepliCel's innovative technology which utilizes cells isolated from a patient's healthy hair follicles. Specific cells are isolated, replicated, and delivered back into the patient. In 2017, RepliCel completed three phase 1 clinical studies including RCH-01 for pattern baldness from Androgenetic Alopecia, RCT-01 for chronic Achilles tendinosis, and RCS-01 for aging and UV-damaged skin. All trials successfully met their primary endpoints and provided significantly positive clinical efficacy data on secondary endpoints. Shiseido Company, the fourth largest cosmetics company in the world, has an exclusive geographic license for RCH-01 in certain Asian countries including Japan, China, and South Korea. They are funding a clinical study in Japan. RepliCel is actively engaging potential partners for its other products. In addition to its cellular products, RepliCel has also developed a proprietary, next-generation dermal injection device (RCI). The device is designed for optimal delivery of RCH-01 and RCS-01 but represents a next-gen dermal injector for use with other dermatological injection procedures.